Press Releases Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

End-of-day quote Nasdaq Other stock markets 23:00:00 04/06/2024 BST			5-day change	1st Jan Change
4.56 ^USD	+2.24%		+2.24%	-2.36%

06-06	Zura Bio Limited Announces Formation of a Scientific Advisory Board	CI
06-03	Zura Bio Limited to Present Data Exploring the Expanded Potential of Tibulizumab Into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology	06-06	BU
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024	06-03	BU
Zura Bio Announces Participation in June Investor Conferences	05-29	BU
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights	05-09	BU
Zura Bio Announces Oversubscribed $112.5 Million Private Placement	04-18	BU
Zura Bio Announces Robert Lisicki as CEO and Director	04-08	BU
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer	03-28	BU
Zura Bio Announces Participation at March Conferences	03-04	BU
Zura Bio Announces Participation at February Investor Conferences	02-02	BU
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO	01-08	BU
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit	01-03	BU
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok	12-04	BU
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors	11-14	BU
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights	11-13	BU
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute	12/09/23	BU
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights	14/08/23	BU
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes	23/06/23	BU
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist	06/06/23	BU
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab, a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases	28/04/23	AQ
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases	27/04/23	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

Press Releases

Filters